drugset / Trial / NCT06843044
Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders
RandomizedParallel-groupOpen-labelTreatment
Summary
Study is to evaluate the efficacy and safety of the drug Ranquilon, 1 mg tablets, at a dosage of 6 mg/day compared to the drug Afobazole, 10 mg tablets, at a dosage of 30 mg/day for the treatment of patients with anxiety disorders due to neurasthenia and adjustment disorders.
Timeline
- Start
- 2025-01-13
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | FABOMOTIZOLE | Small molecule | 30 mg | — |
| Subject | Ranquilon | Unknown | 6 mg | — |